Compare Incyte Corporation (INCY) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Procter & Gamble Co — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.65B), while Procter & Gamble Co trades at $145.13 (market cap $340.39B). The key difference: Procter & Gamble Co is far larger — about 13.8× Incyte Corporation's market cap, and Procter & Gamble Co pays a 2.97% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | PG | |
|---|---|---|
Market Cap | $24.65B | $340.39B |
Sector | Health | Consumer Staples |
52-Week High | $129.93 | $167.18 |
52-Week Low | $81.61 | $138.10 |
Enterprise Value | $20.15B | $366.23B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.56, up 1.84% on the day, near its 52-week high of $120.70. The stock shows a bullish technical trend with strong earnings beats in Q1 and Q2 2026, including Q2 EPS of $3.09 versus $2.15 expected. Revenue growth accelerated to $5.14 billion in 2025, with a net income margin of 27.71%. Recent news highlights EU approval for Opzelura and a raised 2026 revenue outlook, fueling positive momentum.
The outlook remains favorable with analyst consensus at Buy and a $122.82 price target, though risks include reliance on key drugs like Jakafi and competitive pressures. Earnings growth and pipeline advancements support upside, but investors should monitor execution against guidance and regulatory developments.
Procter & Gamble (PG) trades at $146.38, up 0.42% today, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.90. Revenue reached $84.28B in 2025, with a net income margin of 18.44% and robust cash flow from operations of $17.82B. Analyst consensus is bullish with a $161.20 price target, though valuation multiples like P/E of 22.12 and P/S of 4.08 are at premiums to peers.
The outlook for PG is positive due to steady earnings growth and dividend reliability, but risks include premium valuation concerns and soft demand headwinds. Investors may find opportunity in its defensive qualities amid market volatility, though near-term upside could be limited by technical resistance and modest revenue growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
